Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Back
Association details:
Biomarker:
IDH1 mutation + BRAF V600E
Cancer:
Astrocytoma
Drug:
Zelboraf (vemurafenib)
(
BRAF inhibitor
,
BRAF V600E inhibitor
) +
Cotellic (cobimetinib)
(
MEK1 inhibitor
)
Direction:
Sensitive
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
New
Source:
NCCN
Excerpt:
ADULT GLIOMA: IDH-MUTANT ASTROCYTOMA….Recurrent or Progressive Disease WHO grade 2, KPS ≥60...Useful in Certain Circumstances...BRAF V600E activation mutation...BRAF/MEK inhibitors:…Vemurafenib/cobimetinib
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login